Combination therapy for advanced pancreatic cancer after first treatment
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a combination of drugs (an investigational immunotherapy, a targeted therapy, and chemotherapy) as a second-line treatment for people with advanced pancreatic cancer. The goal is to see if this combination can help slow down or stop the cancer when the first treatment no longer works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your pancreatic cancer is locally advanced (cannot be removed with surgery) or has spread to other parts of the body.
- You are able to take care of yourself (up and about, but not necessarily able to do heavy physical work).
- Your cancer has progressed after one prior chemotherapy treatment.
- You have at least one measurable tumor on a scan.
- You are agreeable to providing tumor tissue and blood samples for testing.
- Your organ function is adequate (kidney, liver, bone marrow) as determined by blood tests.
- You are willing to use effective birth control during the study and for 6 months after.
- You are able to give written consent and follow study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (including an investigational immunotherapy and a targeted pill, plus standard chemotherapy) as the first treatment for pancreatic cancer that cannot be removed with surgery. It may help shrink tumors or slow the cancer's growth.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This study tests a combination of three drugs—two pills and one infusion—for people with advanced pancreatic cancer who have already tried one or more treatments. It may help shrink tumors or slow the cancer's growth.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.